Patient Perceptions of Telephone vs. In‐Person <i>BRCA1/BRCA2</i> Genetic Counseling
Beth N. Peshkin(Georgetown University), Marc D. Schwartz(Guardia Civil), Judy E. Garber(Dana-Farber Cancer Institute), Rachel Nusbaum(Icahn School of Medicine at Mount Sinai), Marie Wood(University of Colorado Cancer Center), Lina Jandorf(Icahn School of Medicine at Mount Sinai), Gillian W. Hooker(National Institutes of Health), Tiffani A. DeMarco(Georgetown University), Wendy McKinnon(University of Vermont), Shelley R. McCormick(Georgetown University), Scott P. Kelly(Pfizer (United States)), Claire Rebecca Davis(Sarah Lawrence College), Claudine Isaacs(Georgetown University), Kristi D. Graves(Georgetown University), Heiðdís Valdimarsdóttir(Reykjavík University), Jessica Rispoli Joines(University of Maryland, Baltimore), Morgan Similuk, Andrea Forman(Fox Chase Cancer Center)
Cited by 60
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k